As a result, targeting the PD‐L1 and PD‐1 axis is viewed as a promising strategy for cancer immunotherapy.[5] Therefore, comprehending the molecular mechanisms that regulating PD‐L1 expression is crucial for guiding the clinical application of PD‐1/PD‐L1 immune checkpoint inhibitors. This evidence concerns the gene CD274 and cancer.